Penny Stock 101

[TFMG]

$PSYC | #GlobalTracSolutions - Your Best Bet To Capitalize On Psychedelics Boom



Global Trac Solutions Inc. (PSYC)
Alert Price: $0.0120
Technical Analysis
We hope you enjoyed the up to +93.33% in realistic gains that last Thursday's alert delivered!
That was the perfect way to wrap up a highly profitable month of July, in which our members had the opportunity to secure up to +306% in realistic gains!
We are kicking off the month of August with a fresh trade idea that has triple-digit gain potential.
Please turn your immediate attention to Global Trac Solutions Inc. (PSYC).
PYSC is a diversified holding company dedicated to identifying new and emerging industries. By utilizing their years of business development expertise their diverse team of innovators continuously leverages their experience to effectively execute go-to-market strategies in order to position the Company for rapid growth through the creation of an evolving business foundation to enhance profitability potential.
Just like our most recent winners, PSYC:
Is Highly Diversified
Rapidly Growing
Has An Attractive Share Structure
Recently Released Market Friendly News
The Psychedelics Boom Has Begun
Just last week, the Company announced that daily website traffic analytics observed in recent weeks associated with the Company’s Psychedelic Spotlight website (psychedelicspotlight com) has demonstrated a steady increase in daily visitors which is highlighted by over 4,000 visitors to the site on the 15th of July alone, a new daily record for the website.

The Company contends that a contributing factor to the significant surge in visitors to the website on July 15th was due in large part to the release of the 2nd edition of their Microdose Monthly newsletter to its growing base of subscribers on that day, in addition to the recent launch of its social media platforms, as well as other related networking efforts it is beginning to leverage as a means of increasing its presence within the burgeoning medicinal psychedelic space.

Said Global Trac Solutions, Inc. CEO , David Flores: “It is extremely encouraging to see some of the awareness-driven initiatives we have deployed in recent weeks begin to demonstrate their value through positive data and analytics. As you know, developing a recognized brand and identity for ourselves within the emerging medicinal psychedelic space is a very critical part of placing us on a reasonable path to tapping into a variety of different revenue streams as we forward with our expansion. By driving more traffic to our Psychedelic Spotlight website and increasing subscribership to our Microdose Monthly newsletter, I believe we are in the process of positioning ourselves quite effectively to begin creating revenue opportunities through things like online display advertising in addition to being in a more prominent position to explore potential partnership opportunities within this dynamic space.”

The Company intends to continue the growth of each of its platforms by remaining committed to efforts involved in connecting with some of the most recognized leaders and prominent advocates within the rapidly expanding medicinal psychedelic industry.

We have a feeling that PSYC could be our next trade idea to more than double in price.

That being said, we ask that you add it to the top of your watchlist immediately, and be ready to trade at 9:30AM EST.

About Global Trac Solutions, Inc.

Global Trac Solutions is a diversified holding company dedicated to identifying new and emerging industries. By utilizing our years of business development expertise our diverse team of innovators continuously leverages our experience to effectively execute go-to-market strategies in order to position ourselves for rapid growth through the creation of an evolving business foundation to enhance profitability potential.

PSYC has expressed its intent and commitment to positioning itself at the forefront of the psychedelic revolution and as a resource center for discovering and understanding the latest research and business opportunities surrounding psychedelic inspired medicines. In conjunction with the FDA’s more open-minded approach to psychedelic medicines, and as several major U.S. cities continue to approve the decriminalization of psilocybin, investors are speculating that the psychedelic boom could be bigger than that of cannabis. PSYC is your source for current investment related news specific to psychedelic medicines and cutting-edge research improving overall health, moving this sector into the mainstream.

We believe in a forward-thinking approach that embraces groundbreaking new technology and innovations and through the vision of business development we intend to continue to evolve into these unchartered territories as the industry leaders of the future. We truly are the right TRAC to follow.

PSYC To Exit Cannabis Payments Industry To Redirect Focus on Emerging Psychedelic Market Space

Last month the Company announced to its valued shareholders and stakeholders that in an effort to more strategically focus the Company’s current growth and expansion initiatives within the burgeoning medicinal psychedelic industry, in addition to adapting to the challenges faced within a changing economic climate, the Company has made the decision to wind down all operations associated with its wholly-owned subsidiary, MTrac Tech Corporation effective immediately.

While the Company contends that this decision was not easy given the success MTrac achieved within the retail cannabis industry over the last year and a half, it believes that in order for PSYC to proceed full steam ahead with its push into the psychedelic space, it must make every effort to dedicate as much of its valuable resources towards the pursuit of this initiative.

“Though this decision comes with an understandably heavy heart, I remain extremely proud and eternally grateful of what we were able to accomplish with MTrac and the MTrac brand,” said Global Trac Solutions, Inc. CEO , Vanessa Luna. “We took an entirely new and innovative form of software technology, branded it, marketed it, and successfully delivered it to an industry in need of it the most. The journey associated with the development, launch and success of MTrac was every bit as exhilarating as it was challenging and there are few words to describe how eternally appreciative I am for the dedication and sacrifices made by everyone who was involved in this along the way. However, in now having a full and complete understanding of the demands, complexities, and exorbitant costs which are required to effectively and compliantly operate a business within a sector of an industry whose regulations are constantly shifting across multiplestates, I believe that it is in our best interest from both a financial and growth perspective to focus entirely on our efforts in the emerging psychedelic space.”

In connection with its decision to wind down operations with MTrac, the Company has mutually and amicably cancelled its exclusive licensing agreement with its former technology partner GreenBox POS and will dedicate the next several weeks towards an effective and efficient phase out of any and all remaining business operations within MTrac.

Psychedelics are creating a wellness revolution and an industry with unprecedented opportunity.

Psychedelics are part of a class of psychotropics that are known to activate the serotonin receptors in our brain, which have a direct effect on mood, cognition, and perception.

Their use as a treatment for mental healing and to facilitate spiritual experiences dates back thousands of years in a variety of different cultures across the globe, but for the first time in history, the benefits of psychedelics, backed by recently gained scientific evidence, have shown promise as "breakthrough therapies" in treating a range of cognitive and physical conditions, which have been labeled as treatment-resistant to traditional medicines and therapies.

These new medical studies and the companies at the forefront of the industry's development are changing the way we think about mental health and human consciousness, creating a psychedelic renaissance for global wellness and unprecedented opportunities.

FDA Calls Psychedelic Psilocybin a 'Breakthrough Therapy' for Forms of Depression

The FDA is helping to speed up the process of researching and approving psilocybin, a hallucinogenic substance in magic mushrooms, to treat major depressive disorder ( MDD ).

For the second time in a year, the U.S. Food and Drug Administration (FDA) has designated psilocybin therapy — currently being tested in clinical trials — as "breakthrough therapy," an action that is meant to accelerate the typically sluggish process of drug development and review. It is typically requested by a drug company and granted only when preliminary evidence suggests the drug may be an enormous improvement over already available therapy, according to the FDA.

Last year, the FDA granted "breakthrough therapy" status to psilocybin therapy in the still-ongoing clinical trials run by the company Compass Pathways, which are looking into psilocybin's potential to treat severe treatment-resistant depression, or depression in patients who have not improved after undergoing two different antidepressant treatments, according to New Atlas.

Market Outlook

Magic Mushrooms Could Be the Next Investment Trend

With the market surging back to life, investors are poised to pounce on the next trend. And if you missed out on the biotech boom then you'll want to pay special attention to what's coming next.

This completely new market opportunity may be about to become front page news. Because the FDA just "fast tracked" it. Why? It could help solve a serious problem. Big Pharma's pills for mood disorders just don't work for many people.

Currently, major anti-depressant medications only improve symptoms in 40 to 60 out of 100 people. According to the National Institute of Health, more than 16 million Americans suffered from depression in 2016, while 40 million suffer from anxiety, making it the single most common mental illness in the United States.

For certain groups, it's much worse. About 30% of active-duty and military personnel deployed in Iraq and Afghanistan suffer from mental illness, particularly post-traumatic stress disorder (PTSD) and depression.

Traditional treatments just aren't cutting it for some. But a new set of game-changing "special compounds" like Psilocybin may shake things up.

In the United States alone, Treatment-resistant depression ( TRD ) costs employers up to $48 billion each year, according to a study published in The Journal of Clinical Psychiatry. Arguably, a drug effective in treating a $48 billion dollar problem would have significant potential in the marketplace. In addition, the depression medication market is expected to grow from $14.5 billion in 2014 to nearly $17.0 billion by 2020.

The current reform movement taking place with Psychedelics in North America has many of the same hallmarks that the cannabis industry had in its early days. Back in the day, many wondered if legal cannabis dispensaries would become a reality.

Fast forward a few years and many thousands of marijuana dispensaries later and the same questions are beginning to arise in the new psychedelics space regarding the possibility of legal retail “Shroomeries”. Over the past couple of years, substances like Psilocybin (Magic Mushrooms), Ayahuasca, Peyote, Ketamine, DMT , LSD and MDMA have shown tremendous medical promise in treating conditions such as anxiety, depression, addiction and PTSD.

In response to the many positive medical studies on the health benefits of various psychedelics, a new reform wave has begun to sweep across the United States. Recently, Washington D.C. and Vermont have both put forth legislation aimed at decriminalizing certain psychedelic substances within their state.

Many major U.S. cities such as Denver, Oakland and Santa Cruz have also approved similar decriminalization measures. Just days ago Denver made history by holding the first government psychedelics decriminalization panel where reform advocates were able to speak openly with elected officials and members of local law enforcement about the city’s psychedelics policy and the therapeutic potential of psilocybin mushrooms. Activists in the city of Oakland have even gone as far as to reveal a new plan to legalize the sale of psychedelics in 2020.

Technical Analysis

Just like many of our past winners, PSYC appears to be grossly oversold and undervalued at these levels.

The share structure also seems attractive to those looking for a ticker with monster breakout potential!

We've done our very own chart analysis and see the potential for a big move from here!

Bullish Indicators:

Bullish Cross Above Zero-Line
CMF Approaching Zero-Line, Short Cover Signal
Histogram Rising Bullishly. MACD In Strong Uptrend
The Bottom Line

PSYC Could Be Your Best Best To Capitlaize On The Psychedelics Boom!

If you are on the hunt for monster single-session gains, then PSYC is the only ticker that should be on your radar. By Viewing this Content, you Agree that you Have Read and are in Full Understanding of both our Disclaimer & Privacy Policy(*Remember to use a Stop-Loss Order to protect your gains, as well as limit possible losses.)
Best regards,